Roche will fully acquire Spark Therapeutics in a definitive merger agreement for a price of $114.50 per share.
The total equity value of the deal is approximately $4.8 billion, inclusive of approximately $500 million of projected net cash expected at close, a Spark press release said.
“Spark Therapeutics’ proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious disease,” Roche CEO Severin Schwan said in the release.
Spark will operate as an independent company within the Roche Group and will keep its operations
Uncategorized